Close Menu

NEW YORK – Molecular diagnostic firm Inflammatix announced Tuesday it has received up to $1.1 million from the US Department of Defense's Defense Advanced Research Projects Agency (DARPA) to further develop a rapid diagnostic to predict risk of severe respiratory failure in patients with COVID-19.

The company's CoVerity COVID-19 Severity test is being developed to help clinicians make hospital admission and resourcing decisions. Its host-response diagnostics technology reads the immune system with a machine learning algorithm and 5 mRNA biomarkers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.